TNF and liver failure: Hence, in addition to the TNF‐α inhibitors or neutralizing antibodies that are currently used for treatment, a combination of HMGB1 inhibitors or TNF‐α SNPs can also be considered for the treatment of liver failure and acute kidney injury.